ArticleNPJ vaccines2025
Progress and gaps in poliovirus immunity: Evidence from a serological survey of children aged 6-23 months in high-risk districts of Pakistan.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Wild poliovirus remains endemic in Pakistan and Afghanistan despite global progress. We quantified immunity to poliovirus types 1-3 among children aged 6-23 months in 44 high-risk districts (2022-2023) using a cross-sectional serosurvey with probability proportional to size (PPS) cluster sampling. We enrolled 20,680 children (10,112 aged 6-11 months; 10,568 aged 12-23 months). Seroprevalence among 6-11-month-olds was 94.5% (type 1), 44.6% (type 2), and 88.0% (type 3); among 12-23-month-olds, it was 95.9%, 53.8%, and 91.2%, respectively. Type 1 seropositivity was highest across provinces; type 3 exceeded 90% except in Balochistan and KP; type 2 was lowest everywhere. Younger children have lower immunity. In multivariable models, residence in Balochistan predicted reduced seroprotection (AOR 0.178, 95% CI 0.066-0.484); older age (AOR 1.356, 1.161-1.583), full immunization (AOR 2.004, 1.643-2.444); and receiving <4 oral poliovirus vaccine (OPV) doses showed higher odds (AOR 1.25, 1.021-1.529) of seroprotection. Wealth showed a non-linear association. Gaps in types 2-3 warrant stronger routine immunization, expanded inactivated polio vaccine (IPV), and tailored supplementary immunization activities (SIAs).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.